Key facts
- Kyron.bio’s last known valuation is $15.0M (May 2025).
- It has raised $8.1M; the latest was Seed Round ($6.2M) in May 2025.
- Notable investors include Creative Destruction Lab, Bpifrance, European Innovation Council, Entrepreneurs First, European Commission — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Kyron.bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kyron.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kyron.bio
Operator of a bioproduction platform intended to produce cheap and novel biopharmaceuticals. The company's platform leverages patentable technology that boosts the effectiveness and yield of therapeutic proteins produced in mammalian cell factories by harnessing efficient processes from diverse organisms to precisely control the glycosylation pattern on the surface of a biologic for developing medicines, enabling the bioproduction industry to revolutionize drug production.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 7
- Website
- kyron.bio/
- Ownership
- Privately Held (backing)
Kyron.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kyron.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kyron.bio in its N-PORT filings yet. We sweep new filings monthly.